Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Audited Financial Results For The Year Ended March 31, 2021

 Audited Financial Results for the year ended March 31, 2021. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Management Discussion & Analysis, Press Release, Investor Presentation, Auditors Report and Declaration of unmodified opinion. Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2020 - 21 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
28-05-2021

Market Ahead Podcast, May 28: Top factors that could guide markets today

 A total of 96 companies, including Glenmark Pharma, M&M, Nazara Technologies, and V Mart are scheduled to report their Marhc quarter results today
28-05-2021

Glenmark arm, Emcure, 3 other pharma companies line up Rs 7,000 crore IPOs

 Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research.
27-05-2021

Glenmark Pharma gets USFDA nod for Icatibant Injection

 The approved product is a generic version of Firazyr Injection of Shire Human Genetic Therapies, Inc.
24-05-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe
24-05-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe
24-05-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Enclosed please find herewith the details of Earnings Call slated for Monday, May 31, 2021 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.
20-05-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window

 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, May 28, 2021, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2021 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2021. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2021 to May 30, 2021 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31, 2021.
19-05-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2021 And To Consider And Recommend Dividend, If Any, On Equity Shares For The Year Ended March 31, 2021.

 GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2021 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2021 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2021. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2021 to May 30, 2021 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31, 2021.
19-05-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Reporting Under SEBI (Prohibition Of Insider Trading) Regulations, 2015 For Violation Of Company'S Insider Trading Policy

 This is to inform you that in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015 ('the SEBI Regulations'), Policy for Trading in the securities of Glenmark Pharmaceuticals Limited by an Insider' ('the Policy'), and SEBI Circular No. SEBI/HO/ISD/ISD/CIR/P/2020/135 dated July 23, 2020, the details of violation of the Policy by the Designated Persons along with the action taken by the Company thereon is enclosed as 'Annexure A' to this letter. Request you to kindly take the same on record.
18-05-2021
Next Page
Close

Let's Open Free Demat Account